Literature DB >> 3264121

Cost of nosocomial infection: relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections.

D S Wakefield1, C M Helms, R M Massanari, M Mori, M Pfaller.   

Abstract

This study reports an analysis of the relative importance of laboratory antibiotic, and per diem costs of caring for 58 patients with serious Staphylococcus aureus nosocomial infections. Laboratory costs accounted for 2%, antibiotics for 21%, and per diem costs for 77% of total infection-related costs. Only 45% of patients were hospitalized for additional days specifically because of infection, but these patients stayed an average of 18 extra days. Nosocomial infections with S. aureus resistant to penicillinase-resistant penicillins (PRP) were more frequently associated with additional infection-related days of hospitalization than were PRP-susceptible infections. The cost of PRP-resistant infections was also significantly greater than PRP-susceptible infections, primarily because of the costs of additional days of hospitalization. Rational strategies to control costs of nosocomial infection should focus on two approaches: (1) prevention and (2) reduction of acute hospital days attributable to infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264121     DOI: 10.1016/0196-6553(88)90058-2

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  14 in total

1.  Methicillin-Resistant Staphylococcus aureus Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

Review 2.  [Methicillin-resistant Staphylococcus aureus. Types of resistance and clinical consequences].

Authors:  U Geipel; M Herrmann
Journal:  Anaesthesist       Date:  2005-02       Impact factor: 1.041

3.  Economical saving due to prophylaxis in the prevention of surgical wound infection.

Authors:  M Fernandez Arjona; R Herruzo Cabrera; F Gomez-Sancha; S Nieto; J Rey Calero
Journal:  Eur J Epidemiol       Date:  1996-10       Impact factor: 8.082

Review 4.  Costs of hospital-acquired infection and transferability of the estimates: a systematic review.

Authors:  H Fukuda; J Lee; Y Imanaka
Journal:  Infection       Date:  2011-03-22       Impact factor: 3.553

5.  Using cost of infection as a tool to demonstrate a difference in prophylactic antibiotic efficacy: a prospective randomized comparison of the pharmacoeconomic effectiveness of ceftriaxone and cefotaxime prophylaxis in abdominal surgery.

Authors:  John C Woodfield; Andre M Van Rij; Ross A Pettigrew; Antje van der Linden; Donna Bolt
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

Review 6.  Epidemiology, therapy and costs of nosocomial infection.

Authors:  R Gálvez-Vargas; A Bueno-Cavanillas; M García-Martín
Journal:  Pharmacoeconomics       Date:  1995-02       Impact factor: 4.981

Review 7.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

8.  The evolution of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 5 years of national surveillance.

Authors:  A E Simor; M Ofner-Agostini; E Bryce; K Green; A McGeer; M Mulvey; S Paton
Journal:  CMAJ       Date:  2001-07-10       Impact factor: 8.262

9.  The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper.

Authors:  Andrew E Simor; Mark Loeb
Journal:  Can J Infect Dis       Date:  2004-01

10.  Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients.

Authors:  T J Babineau; P Marcello; W Swails; A Kenler; B Bistrian; R A Forse
Journal:  Ann Surg       Date:  1994-11       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.